MARKET

A Critical Sector Ripe for Consolidation

Targeting the Booming Biopharma Market

Growth in the biopharma CDMO market

Source: ResearchandMarkets

VC biotech investments in 2017 VS 2021

Source: Frost & Sullivan

Significant room for further consolidation

Source: WuXi Biologics 2019 Annual Result

– Highly fragmented market and large target reservoir.


– Substantial consolidation trend 

(c. 40-60 transactions p.a.).


– More than 1,000 companies: 2/3 generating less than $50m revenues.

Source: WuXi Biologics 2019 Annual Result

– Highly fragmented market and large target reservoir.


– Substantial consolidation trend 

(c. 40-60 transactions p.a.).


– More than 1,000 companies: 2/3 generating less than $50m revenues.

Strong Ramp-Up of Transaction Activity in the Biopharma CDMO Space – Expected to Continue

Source: WuXi Biologics 2019 Annual Result

CDMO Expertise Present Alongside the Whole Drug Development Chain

eureKING

128 rue de la Boétie, 75008 Paris, France

info@eureKING.com

Press Contacts

Image Sept

Leslie Jung-Isenwater/Sergio de la Calle/Florence Coupry

+33 (0)1 53 70 74 70 

eureking@image7@.fr